Journal
ADVANCED SCIENCE
Volume 10, Issue 7, Pages -Publisher
WILEY
DOI: 10.1002/advs.202206169
Keywords
cancer treatment; DNA methylation; histone modification; nanotechnology; tumor microenvironment
Ask authors/readers for more resources
Dysregulated epigenetic modifications drive tumor progression, drug resistance, and metastasis by affecting the tumor microenvironment. Therapies targeting epigenetic dysregulation show promise, but clinical results of combination therapies are disappointing due to toxicities and limited effectiveness. This article discusses the role of epigenetic processes, the regulation of the tumor microenvironment, and the use of advanced drug delivery system for targeted therapy.
Dysregulated epigenetic modifications dynamically drive the abnormal transcription process to affect the tumor microenvironment; thus, promoting cancer progression, drug resistance, and metastasis. Nowadays, therapies targeting epigenetic dysregulation of tumor cells and immune cells in the tumor microenvironment appear to be promising adjuncts to other cancer therapies. However, the clinical results of combination therapies containing epigenetic agents are disappointing due to systemic toxicities and limited curative effects. Here, the role of epigenetic processes, including DNA methylation, post-translational modification of histones, and noncoding RNAs is discussed, followed by detailed descriptions of epigenetic regulation of the tumor microenvironment, as well as the application of epigenetic modulators in antitumor therapy, with an emphasis on the epigenetic-based advanced drug delivery system in targeting the tumor microenvironment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available